多囊卵巢综合征与代谢综合征相关研究进展
Research Progress of Polycystic Ovary Syndrome and Metabolic Syndrome
DOI: 10.12677/MD.2023.133058, PDF,   
作者: 马 宁, 陈 哲：延安大学临床医学院，陕西 延安；高成英*：延安大学附属医院妇科，陕西 延安
关键词: 多囊卵巢综合征；胰岛素抵抗；代谢综合征；肥胖；血脂异常；Polycystic Ovary Syndrome； Insulin Resistance； Metabolic Syndrome； Obesity； Dyslipidemia
摘要: 多囊卵巢综合征(polycystic ovarian syndrome, PCOS)是育龄期妇女常见的一种异质性内分泌疾病，发病原因复杂，且发病机制尚不明确。代谢综合征(metabolic syndrome, MS)是一组以腹型肥胖、空腹血糖受损、高血压、血脂异常为特征的代谢紊乱症候群。二者的临床表现有着高度的相似性，它们之间的关系至今尚不明确。PCOS合并代谢综合征时可增加心血管疾病和II型糖尿病发生的风险。而代谢综合征的诊断标准并不统一，所以对于PCOS合并代谢综合征的识别显得尤为重要。本文通过对PCOS和代谢综合征的危险因素进行综述，进而分析二者间的联系，以便早期识别PCOS合并代谢综合征。
Abstract: Polycystic ovary syndrome (PCOS) is a common heterogeneous endocrine disease in women of childbearing age, with complex causes and unclear pathogenesis. Metabolic syndrome (MS) is a metabolic disorder syndrome characterized by abdominal obesity, impaired fasting blood glucose, hypertension, and abnormal blood lipids. The clinical manifestations of the two are highly similar, and the relationship between them is still unclear. PCOS combined with metabolic syndrome can increase the risk of cardiovascular disease and type II diabetes. The diagnostic criteria for metabol-ic syndrome are not unified, so the recognition of PCOS combined with metabolic syndrome is par-ticularly important. This article reviews the risk factors of PCOS and metabolic syndrome, and ana-lyzes the relationship between the two in order to early identify PCOS combined with metabolic syndrome.
文章引用：马宁, 陈哲, 高成英. 多囊卵巢综合征与代谢综合征相关研究进展[J]. 医学诊断, 2023, 13(3): 381-387. https://doi.org/10.12677/MD.2023.133058

参考文献

[1] Escobar-Morreale, H.F. (2018) Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment. Nature Reviews Endocrinology, 14, 270-284. [Google Scholar] [CrossRef] [PubMed]
[2] Joham, A.E., et al. (2022) Polycystic Ovary Syndrome. The Lancet Diabetes and Endocrinology, 10, 668-680. [Google Scholar] [CrossRef] 
[3] Siddiqui, S., Mateen, S., Ahmad, R. and Moin, S. (2022) A Brief Insight into the Etiology, Genetics, and Immunology of Polycystic Ovarian Syndrome (PCOS). Journal of Assisted Reproduc-tion and Genetics, 39, 2439-2473. [Google Scholar] [CrossRef] [PubMed]
[4] Garg, A., Patel, B., Abbara, A. and Dhillo, W. (2022) Treatments Tar-geting Neuroendocrine Dysfunction in Polycystic Ovary Syndrome (PCOS). Clinical Endocrinology, 97, 156-164. [Google Scholar] [CrossRef] [PubMed]
[5] Ding, H., et al. (2021) Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Frontiers in Endocrinology, 12, Article 741764. [Google Scholar] [CrossRef] [PubMed]
[6] Hernández-Jiménez, J.L., et al. (2022) Polycystic Ovarian Syndrome: Signs and Feedback Effects of Hyperandrogenism and Insulin Resistance. Gynecological Endocrinology, 38, 2-9. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, Y.C., et al. (2023) Hyperandrogen-Induced Polyol Pathway Flux Increase Affects Ovarian Function in Polycystic Ovary Syndrome via Excessive Oxidative Stress. Life Sciences, 313, Arti-cle ID: 121224. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, Y. and Qiao, J. (2022) Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature. Journal of Healthcare Engineering, 2022, Article ID: 9240569. [Google Scholar] [CrossRef] [PubMed]
[9] Ollila, M.-M., et al. (2023) Women with PCOS Have an Increased Risk for Cardiovascular Disease Regardless of Diagnostic Criteria—A Prospective Population-Based Cohort Study. European Journal of Endocrinology, 189, 96-105. [Google Scholar] [CrossRef] [PubMed]
[10] Saklayen, M.G. (2018) The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 20, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
[11] Bahadur, A., et al. (2021) Prevalence of Metabolic Syndrome among Women with Different PCOS Phenotypes—A Prospective Study. Gyneco-logical Endocrinology, 37, 21-25. [Google Scholar] [CrossRef] [PubMed]
[12] Amisi, C.A. (2022) Markers of Insulin Resistance in Polycystic Ovary Syndrome Women: An Update. World Journal of Diabetes, 13, 129-149. [Google Scholar] [CrossRef] [PubMed]
[13] Li, X., et al. (2022) The Degree of Menstrual Disturbance Is Associated with the Severity of Insulin Resistance in PCOS. Frontiers in Endocrinology, 13, Article 873726. [Google Scholar] [CrossRef] [PubMed]
[14] Johnson, J.-E., Daley, D., Tarta, C. and Stanciu, P.I. (2023) Risk of En-dometrial Cancer in Patients with Polycystic Ovarian Syndrome: A Meta-Analysis. Oncology Letters, 25, Article No. 168. [Google Scholar] [CrossRef] [PubMed]
[15] Hanna, F., Wu, P., Heald, A. and Fryer, A. (2023) Diabetes Detection in Women with Gestational Diabetes and Polycystic Ovarian Syndrome. BMJ, 382, e071675. [Google Scholar] [CrossRef] [PubMed]
[16] Livadas, S., et al. (2023) Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome. Diagnostics, 13, Article No. 2067. [Google Scholar] [CrossRef] [PubMed]
[17] Zhao, H., Zhang, J., Cheng, X., Nie, X. and He, B. (2023) Insulin Re-sistance in Polycystic Ovary Syndrome across Various Tissues: An Updated Review of Pathogenesis, Evaluation, and Treat-ment. Journal of Ovarian Research, 16, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[18] Rajkhowa, M., et al. (2009) Insulin Resistance in Polycystic Ovary Syndrome Is Associated with Defective Regulation of ERK1/2 by Insulin In Skeletal Muscle in Vivo. Biochemical Journal, 418, 665-671. [Google Scholar] [CrossRef] 
[19] Herman, R., Sikonja, J., Jensterle, M., Janez, A. and Dolzan, V. (2023) Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance. International Journal of Molecular Sciences, 24, Article No. 3140. [Google Scholar] [CrossRef] [PubMed]
[20] Lazaridou, S., Dinas, K. and Tziomalos, K. (2017) Prevalence, Pathogenesis and Management of Prediabetes and Type 2 Diabetes Mellitus in Patients with Polycystic Ovary Syndrome. Hormones, 16, 373-380. [Google Scholar] [CrossRef] [PubMed]
[21] Kakoly, N.S., et al. (2018) Ethnicity, Obesity and the Prevalence of Im-paired Glucose Tolerance and Type 2 Diabetes in PCOS: A Systematic Review and Meta-Regression. Human Reproduction Update, 24, 455-467. [Google Scholar] [CrossRef] [PubMed]
[22] Ademoglu, E.N., et al. (2014) Plasma Nesfatin-1 Levels Are Increased in Patients with Polycystic Ovary Syndrome. Journal of Endocrinological Investigation, 37, 715-719. [Google Scholar] [CrossRef] [PubMed]
[23] Makhija, N., Tayade, S., Toshniwal, S. and Tilva, H. (2023) Clini-co-Metabolic Profile in Lean versus Obese Polycystic Ovarian Syndrome Women. Cureus, 15, e37809. [Google Scholar] [CrossRef] [PubMed]
[24] Pan, X. (2023) Metabolic Characteristics of Obese Patients with Polycystic Ovarian Syndrome: A Meta-Analysis. Gynecological Endocrinology, 39, Article 2239934. [Google Scholar] [CrossRef] [PubMed]
[25] 邵伟维, 孔芳芳, 李丽霞, 高巧玲. 育龄妇女多囊卵巢综合征发病情况调查及影响因素分析[J]. 中国妇幼保健, 2022, 37(7): 1268-1271.
[26] 孟宪芹, 等. 北京市大兴区多囊卵巢综合征患病情况调查及相关危险因素分析[J]. 中国妇幼保健, 2021, 36(24): 5764-5767.
[27] Fouks, Y., et al. (2023) ART Outcomes in Lean Compared to Obese Phenotypes of Polycystic Ovarian Syndrome. Journal of Assisted Reproduction and Genetics, 40, 1437-1445. [Google Scholar] [CrossRef] [PubMed]
[28] Li, J., et al. (2023) Effect of body Mass Index on the Cumulative Live Birth Rate over Multiple Complete IVF Cycles in Women with Polycystic Ovary Syndrome: A Retro-spective Study. Obesity Research & Clinical Practice, 17, 130-136. [Google Scholar] [CrossRef] [PubMed]
[29] Legro, R.S., Kunselman, A.R. and Dunaif, A. (2001) Prevalence and Predictors of Dyslipidemia in Women with Polycystic Ovary Syndrome. The American Journal of Medicine, 111, 607-613. [Google Scholar] [CrossRef] 
[30] Orio Jr., F., et al. (2004) The Cardiovascular Risk of Young Wom-en with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study. The Journal of Clinical Endocrinology & Metabolism, 89, 3696-3701. [Google Scholar] [CrossRef] [PubMed]
[31] El-Mazny, A., Abou-Salem, N., El-Sherbiny, W. and El-Mazny, A. (2010) Insulin Resistance, Dyslipidemia, and Metabolic Syndrome in Women with Pol-ycystic Ovary Syndrome. International Journal of Gynecology & Obstetrics, 109, 239-241. [Google Scholar] [CrossRef] [PubMed]
[32] Li, R., et al. (2013) Prevalence of Polycystic Ovary Syndrome in Women in China: A Large Community-Based Study. Human Reproduction, 28, 2562-2569. [Google Scholar] [CrossRef] [PubMed]
[33] Alberti, K.G.M.M., et al. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and In-ternational Association for the Study of Obesity. Circulation, 120, 1640-1645. [Google Scholar] [CrossRef] 
[34] Lim, S.S., et al. (2019) Metabolic Syndrome in Polycys-tic Ovary Syndrome: A Systematic Review, Meta-Analysis and Meta-Regression. Obesity Reviews, 20, 339-352. [Google Scholar] [CrossRef] [PubMed]
[35] Karee, M., et al. (2020) Prevalence of Metabolic Syndrome in Women with Poly-cystic Ovary Syndrome and the Factors Associated: A Cross Sectional Study at a Tertiary Care Center in Hyderabad, South-Eastern India. Diabetology & Metabolic Syndrome, 14, 583-587. [Google Scholar] [CrossRef] [PubMed]
[36] Krentowska, A. and Kowalska, I. (2022) Metabolic Syndrome and Its Components in Different Phenotypes of Polycystic Ovary Syndrome. Diabetes/Metabolism Research and Reviews, 38, e3464. [Google Scholar] [CrossRef] [PubMed]
[37] Zaeemzadeh, N., et al. (2020) Prevalence of Metabolic Syndrome in Four Pheno-types of PCOS and Its Relationship with Androgenic Components among Iranian Women: A Cross-Sectional Study. Interna-tional Journal of Reproductive BioMedicine, 18, 253-264. [Google Scholar] [CrossRef] [PubMed]
[38] Ye, Z., et al. (2022) Amino Acid Signatures in Relation to Polycystic Ovary Syndrome and Increased Risk of Different Metabolic Disturb-ances. Reproductive BioMedicine Online, 44, 737-746. [Google Scholar] [CrossRef] [PubMed]
[39] He, H., et al. (2021) The Apolipoprotein B/A1 Ratio Is Associated with Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women with Polycystic Ovary Syndrome. Frontiers in Endocrinology, 12, Article 773781. [Google Scholar] [CrossRef] [PubMed]